ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

39 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants231 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Phase 2ImmunodeficiencyHematopoietic Stem Cell Transplantation

Allogeneic HSCTBusulfan test doseMycophenolate mofetil (MMF)+6 more

National Cancer Institute (NCI)54 participants1 site · United StatesCompletes Jul 2031

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants51 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Phase 1Phase 2Lupus Erythematosus, SystemicSystem; SclerosisANCA Associated Vasculitis

CAR T cell

Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)10 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

1–15 of 39

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

39 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

NipocalimabPlaceboStandard of care treatment

Janssen Research & Development, LLC600 participants231 sites · United States, Argentina, AustraliaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Phase 2ImmunodeficiencyHematopoietic Stem Cell Transplantation

Allogeneic HSCTBusulfan test doseMycophenolate mofetil (MMF)+6 more

National Cancer Institute (NCI)54 participants1 site · United StatesCompletes Jul 2031

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants51 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 2Common Variable Immunodeficiency (CVID)Primary Immune Regulatory DisorderImmune Dysregulation

Hematopoietic stem cell transplant (HSCT)

Paul Szabolcs25 participants1 site · United StatesCompletes May 2030

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Phase 1Phase 2Lupus Erythematosus, SystemicSystem; SclerosisANCA Associated Vasculitis

CAR T cell

Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 participants1 site · ItalyCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)10 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

1–15 of 39